Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pregnancy Registries Are Insufficient To Assess Drug Safety, US FDA Says

Executive Summary

Draft guidance recommends complementary studies to evaluate effects of drug use during pregnancy; FDA may require lactation studies more frequently.

You may also be interested in...



EMA Aims For Better Info On Benefit-Risk Balance To Support Drug Choices In Pregnancy

The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.

US FDA’s Higher Bar For Postmarketing Pregnancy Studies Shown By AMAG’s Vyleesi, Sprout’s Addyi

Agency’s postmarketing requirements to assess Vyleesi risk in pregnant and lactating women highlight the changes catalyzed by draft guidances issued in April.

Beyond Pregnancy Registries: Complementary Post-Marketing Approaches

New techniques cannot replace registries but can address their limitations, stakeholders tell FDA.

Topics

UsernamePublicRestriction

Register

PS125253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel